Seminars in Oncology

Papers
(The median citation count of Seminars in Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment40
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance39
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer28
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review26
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis18
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics17
Editorial Board17
Military exposures and lung cancer in United States Veterans16
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer15
Role of neoadjuvant pembrolizumab in advanced melanoma15
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations13
Editorial Board12
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response12
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans12
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis12
Table of Contents12
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer11
Editorial Board11
Masthead10
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review10
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment9
Masthead9
Acute liver failure secondary to malignant infiltration: A single center experience9
Editorial Board8
Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use8
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward8
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.8
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer8
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)8
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population7
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care7
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review7
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t7
Current and prospective antibody-based therapies in multiple myeloma6
Masthead6
A narrative review of the principal glucocorticoids employed in cancer6
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities6
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors6
Barriers and facilitators to lung cancer screening and follow-up6
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment5
Masthead5
Editorial Board5
Radiation recall dermatitis: A review of the literature5
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects5
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty5
outside front cover5
Are we there yet? Gut microbiota for cancer diagnosis, prognosis and treatment4
Daratumumab: A review of current indications and future directions4
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data4
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety4
Masthead4
Table of Contents3
Comorbidity and life expectancy in shared decision making for lung cancer screening3
Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA3
Outside front cover3
outside front cover3
PARP inhibitors in ovarian cancer3
Masthead3
TOC3
Outcomes with panobinostat in heavily pretreated multiple myeloma patients3
The impact of the COVID-19 pandemic on tertiary care cancer center: Analyzing administrative data3
Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: A systematic review and meta-analysis3
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review2
Table of Contents2
Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma?2
Outside front cover2
TOC2
Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives2
The critical role of NLRP3 in drug resistance of cancers: Focus on the molecular mechanisms and possible therapeutics2
Lung cancer screening at the VA: Past, present and future2
outside front cover2
Scoping to analyze oncology trial participation in Australia2
Fingerprint change as a consequence of anticancer treatments: A systematic integrative review2
TOC1
Editorial Board1
Divergent functions of TLRs in gastrointestinal (GI) cancer: Overview of their diagnostic, prognostic and therapeutic value1
Epidemiology and prevention of gastric cancer: A comprehensive review1
The dual effect of interferon-γ in acute myeloid leukemia: A narrative review1
Overcoming barriers to opioid-induced constipation management in cancer patients1
Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents1
Table of Contents1
Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer1
Non-small cell lung cancer in the era of immunotherapy1
Editorial Board1
Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias1
Epidemiology and genetics of early onset colorectal cancer—African overview with a focus on Ethiopia1
TOC1
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis1
Masthead1
Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management1
The Crucial Nexus: Unveiling the Role of Collagen in Cancer Progression1
TOC1
Current perspectives, guiding lights to the future, and transforming care for patients with multiple myeloma1
Editorial Board1
Lung cancer: Premalignant biology and medical prevention1
TOC1
Outside front cover1
0.38744378089905